Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on November 17th, 2023%
Health authorities in Sweden authorized the start of a clinical trial testing insulin-producing cells from donors engineered to prevent immune reactions in people with type 1 diabetes. . . . → Read More: Trial Okayed to Transplant Donated Islet Cells for Type 1 Diabetes
By Alan, on November 16th, 2023%
Generate:Biomedicines describes its Chroma generative A.I. model in yesterday’s issue of the journal Nature, and is making the model available as open source through GitHub. . . . → Read More: Generative A.I. Designs Novel Synthetic Proteins
By Alan, on November 15th, 2023%
A clinical trial in a small group of participants suggests a cannabinoid drug is safe and well-tolerated, and reduces agitation among patients with Alzheimer’s disease. . . . → Read More: Cannabinoid Shown Safe, Lowers Agitation in Alzheimer’s Patients
By Alan, on November 14th, 2023%
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria
By Alan, on November 10th, 2023%
Results of a clinical trial show a peanut allergy treatment formulated as a toothpaste can safely deliver immunotherapy to raise recipients’ peanut tolerance. . . . → Read More: Peanut Allergy Toothpaste Shown Safe in Trial
By Alan, on November 9th, 2023%
A new challenge competition with $1 million in prizes seeks novel techniques for conducting biomedical research with data on human physiology and artificial intelligence. . . . → Read More: Challenge Seeks Transformative Human/A.I. Research Tech
By Alan, on November 7th, 2023%
A virtual reality program conducted at home is shown in a clinical trial to relieve chronic lower back pain intensity and improve daily living more than a sham V.R. program. . . . → Read More: Home V.R. Therapy Shown to Reduce Back Pain
By Alan, on November 6th, 2023%
Results of a clinical trial show a lung cancer therapy using highly focused pulses with electrical energy show signs of immune responses that can treat the patients’ tumors. . . . → Read More: Electric Pulses Induce Lung Cancer Immune Response
By Alan, on October 21st, 2023%
A poll in the U.S. shows a large majority of Americans who heard of artificial intelligence have very little or no trust that companies will use the technology responsibly. . . . → Read More: Infographic – Little Trust in Companies’ A.I. Use
By Alan, on October 20th, 2023%
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|